Evidence map›Paper›PMID 32362566›Full record

ArticleGynecologic oncology2020

Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).

Jeanine N Staples, Lauren C Peres, Fabian Camacho, Anthony J Alberg, Elisa V Bandera, Jill Barnholtz-Sloan, Melissa L Bondy, Michele L Cote, Ellen Funkhouser, Patricia G Moorman and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 1 country.

Jeanine N StaplesDivision of Gynecology Oncology, Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA. Electronic address: js6qf@hscmail.mcc.virginia.edu.
Lauren C PeresDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Fabian CamachoDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Anthony J AlbergDepartment of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Elisa V BanderaDepartment of Population Science, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Jill Barnholtz-SloanDepartment of Population and Quantitative Health Sciences and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Melissa L BondyCancer Prevention and Population Sciences Program, Baylor College of Medicine, Houston, TX, USA.
Michele L CoteKarmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Ellen FunkhouserDivision of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Patricia G MoormanDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
Edward S PetersEpidemiology Program, Louisiana State University Health Sciences Center School of Public Health, New Orleans, LA, USA.
Ann G SchwartzKarmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Paul D TerryDepartment of Medicine, University of Tennessee Medical Center - Knoxville, Knoxville, TN, USA.
Joellen M SchildkrautEmory University Rollins School of Public Health, Atlanta, GA, USA.
University of Virginia · USBaylor College of Medicine · USCase Western Reserve University · USDuke University Hospital · USEmory University · USLouisiana State University Health Sciences Center New Orleans · USMoffitt Cancer Center · USRutgers Cancer Institute of New JerseyThe Barbara Ann Karmanos Cancer Institute · USUniversity of Alabama at Birmingham · USUniversity of South Carolina · USUniversity of Tennessee at Knoxville · USWayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Epidemiology of Ovarian Cancer in African-American WomenR01CA142081 · NCI · UNIVERSITY OF VIRGINIA · PI SCHILDKRAUT, JOELLEN M. · 2010 to 2015
$10.6M
NCI NIH HHS HHSN261201000028CNCI NIH HHS P30 CA022453NCI NIH HHS R01 CA142081NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

backgroundStudies that have examined the association between cardiovascular comorbidities and epithelial ovarian cancer (EOC) have yielded inconsistent results. It remains unknown whether cardiometabolic disease is associated with EOC in African American (AA) women, who have a higher prevalence of cardiovascular disease and lower risk of EOC than White women. Here, we estimate the effect of cardiovascular comorbid conditions and EOC risk among AA women.

methodsData were available from 593 ovarian carcinoma patients and 752 controls enrolled in the African American Cancer Epidemiology Study (AACES). Participants were asked to self-report a history of hypertension, hyperlipidemia, and diabetes and any current medication use. The relationship between hypertension, hyperlipidemia, diabetes, and medications taken for these conditions was determined using multivariate logistic regression.

resultsHypertension was associated with an increased risk (adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.01, 1.73), whereas diabetes and hyperlipidemia were associated with a decreased risk (aOR = 0.67, 95% CI = 0.49, 0.91 and aOR = 0.61, 95% CI = 0.47, 0.80, respectively) of EOC. Use of anti-diabetic medication was inversely associated with EOC risk, as was use of lipid lowering medications (in the overall study population), which were predominantly statins. Among women with hypertension, use of anti-hypertensive medications was inversely associated with EOC risk, with associations that were most pronounced for diuretics, ARBs and ACE inhibitors.

conclusionHypertension was associated with an increased EOC risk in this patient population, whereas an inverse association was observed for diabetes and hyperlipidemia. The decreased risk of EOC identified with use of anti-hypertensive, anti-diabetes or lipid-lowering medications could have implications for risk reduction strategies.

Indexed as

AgedBlack or African AmericanCarcinoma, Ovarian EpithelialCase-Control StudiesDiabetes MellitusFemaleHumansHyperlipidemiasHypertensionMetabolic DiseasesMiddle AgedOvarian NeoplasmsPrevalenceUnited StatesCardiovascular diseaseDisparitiesOvarian cancer risk

Identifiers

PMID32362566
PMCPMC8436266
OpenAlexW3023288147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.